Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19
{{output}}
Background: Bemnifosbuvir, a novel, oral, nonmutagenic, nonteratogenic nucleotide analogue inhibits SARS-CoV-2 replication in vitro. Materials & methods: ... ...
